J1 [129S4/SvJae] Developed by Masaki Okano and En Li, Massachusetts General Hospital in 1999. J1 ES cells were used to generate the mutant mice. The mutant mice were crossed to C57BL/6. 条件を付加する。<br>A. RECIPIENT must send a copy of the executed MTA between RECIPIENT and RIKEN BRC to: Massachusetts General Hospital c/o Partners Innovation, Attn: TAG/MGH MTA 2020A005592, 399 Revolution Drive/Ste 950E, Somerville,MA 02245, USA (phsmta@partners.org). B. Any publication or public disclosure of research results obtained by the use of the BIOLOGICAL RESOURCE shall cite Massachusetts General Hospital in Boston, MA as the source of the material. However, neither the name, trademark, service mark, logo nor other identifying characteristic ("Name") of MGH or any of its affiliates, or any of its or their respective directors, trustees, officers, appointees, employees, staff, representatives or agents, in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the MGH Department of Public Affairs. C. In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature Cell 1999 99:247-57 as designated by the DEPOSITOR is required. D. The use of the BIOLOGICAL RESOURCE is restricted to academic researchers in non-profit organizations for their internal research and educational purposes. E. The BIOLOGICAL RESOURCE shall not be used for commercial purposes. Any request for the BIOLOGICAL RESOURCE by a for-profit entity shall be referred to Massachusetts General Hospital through the Research and Licensing Office. F. Recipients shall assume all liability for their use, storage, handling and disposal of the BIOLOGICAL RESOURCE. The General Hospital Corporation d/b/a Massachusetts General Hospital will not be liable to the Recipients for any loss, claims, matters, damages, costs or liabilities relating to any third party actions, proceedings, investigations, or matters arising from any use, storage, handling, or disposal of the BIOLOGICAL RESOURCE by Recipient. Dnmt3b<tm1Enl>; Dnmt3b null KO Dnmt3b<tm1Enl>; Dnmt3b null KO Dnmt3b遺伝子のノックアウトマウス。Dnmt3b遺伝子座の酵素活性に必須なモチーフをコードする領域を欠損しており、Dnmt3b完全欠損変異と考えられる。哺乳類は、互いに高いアミノ酸配列類似性のある二つのDe novo型DNAメチル化酵素Dnmt3a、Dnmt3bを持つ。両者は異なるアイソフォーム、発現パターンを示し、互いに重複する機能とそれぞれに特異的な機能を持つ。ホモノックアウトマウスは、ホモマウスは胎生14.5-16.5日で致死となる、形態的異常はみとめられないものの、胚全体に浮腫、異所的出血、胎仔肝形成不全、心室隔壁異常を呈する。動原体近傍反復配列におけるDNAメチル化低下が認められる。ホモ胚から作成した胚繊維が細胞 (MEFs) は増殖能低下、細胞老化、染色体異常を起こす。Agouti遺伝子座に連鎖している。Dnmt3aノックアウトマウス (RBRC03730) 、Dnmt3a floxedマウス (RBRC03731) 、Dnmt3b floxedマウス (RBRC03733) 。 B6;129S4-Dnmt3b<tm1Enl> B6;129S4-Dnmt3b<tm1Enl> true C (3-6 months) Fluorescent Proteins/lacZ System Heterozygote x Wild-type [C57BL/6NCrlCrlj] Heterozygote x Wild-type [C57BL/6NCrlCrlj] <a href='https://brc.riken.jp/mus/pcr03732'>Genotyping protocol -PCR-</a> Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Please use the MATERIAL TRANSFER AGREEMENT for Distribution <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx"> for non-profit</A> or <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c_P.docx"> for profit</A> (English only).</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> C（3〜6か月） Masaki OKANO 岡野　正樹 RBRC03732 A. RECIPIENT must send a copy of the executed MTA between RECIPIENT and RIKEN BRC to: Massachusetts General Hospital c/o Partners Innovation, Attn: TAG/MGH MTA 2020A005592, 399 Revolution Drive/Ste 950E, Somerville,MA 02245, USA (phsmta@partners.org). B. Any publication or public disclosure of research results obtained by the use of the BIOLOGICAL RESOURCE shall cite Massachusetts General Hospital in Boston, MA as the source of the material. However, neither the name, trademark, service mark, logo nor other identifying characteristic ("Name") of MGH or any of its affiliates, or any of its or their respective directors, trustees, officers, appointees, employees, staff, representatives or agents, in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the MGH Department of Public Affairs. C. In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature Cell 1999 99:247-57 as designated by the DEPOSITOR is required. D. The use of the BIOLOGICAL RESOURCE is restricted to academic researchers in non-profit organizations for their internal research and educational purposes. E. The BIOLOGICAL RESOURCE shall not be used for commercial purposes. Any request for the BIOLOGICAL RESOURCE by a for-profit entity shall be referred to Massachusetts General Hospital through the Research and Licensing Office. F. Recipients shall assume all liability for their use, storage, handling and disposal of the BIOLOGICAL RESOURCE. The General Hospital Corporation d/b/a Massachusetts General Hospital will not be liable to the Recipients for any loss, claims, matters, damages, costs or liabilities relating to any third party actions, proceedings, investigations, or matters arising from any use, storage, handling, or disposal of the BIOLOGICAL RESOURCE by Recipient. mouse En-2 splice acceptor, Encephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), E. coli LacZ, E. coli neomycin registance gene, SV40 poly A signal sequence, mouse Dnmt3b genomic DNA Dnmt3b knockout mice. A 2.4 kb region encoding the PC and EV motifs was replaced with an IRES-beta-geo cassette. Homozygous mutant mice are embryonic lethal (E14.5-16.5). Dnmt3a knockout mice (RBRC03730), Dnmt3a floxed mice (RBRC03731), Dnmt3b floxed mice (RBRC03733). Massachusetts General Hospital・岡野正樹先生、En Li（1999）。J1 ES細胞を用いて作出。